In 2010, the clinical trials market in Poland is expected to grow by 5% year on year, and to reach PLN 718m (€170m), according to the latest report by PMR, a research and consulting company, entitled “Clinical trials in Poland 2010. Development forecasts for 2010-2012”.

Market worth PLN 718m in 2010

The clinical trials market in Poland slowed in 2009, in comparison with previous years. Between 2006 and 2008, it grew at a rate of 8-10% per annum, whereas 2009 saw a year-on-year increase of only 1%, based on PMR estimates. “This poor market growth rate was, evidently, caused by the economic crisis, as a result of which companies cut down on expenditure on R&D projects, including clinical trials. On the other hand, the market is already quite saturated, which is why, according to us, it is not expected to grow at an exponential rate in the future” says Agnieszka Stawarska, a PMR Pharmaceutical Market Analyst and the report co-author. PMR forecasts that in 2010 the market will expand by around 5% year on year and will be worth PLN 718m (€170m).

Work on Clinical Trials Act still in progress

The Clinical Trials Act has been in preparation for years; the objective of the act is the regulation of clinical trials through the clarification of existing regulations and the addition of new areas which have not previously been subject to legal regulation. The assumptions underlying the bill were published in December 2009, whereas the bill is expected to be ready in the first half of 2010.
Among other things, the Clinical Trials Act will clarify and amend regulations applicable to the proceedings of ethics committees. The bill is based on the assumption that a clinical research coordinator (chosen from among the principal investigators) will be required to file applications with the bioethics committee with jurisdiction over the coordinator’s registered office and with all of the relevant bioethics committees with jurisdiction over the location at which the clinical trial is carried out. In addition, the bill proposes the introduction of an obligation to publish information on clinical trials run in Poland on publicly available websites.
If the assumptions underlying the bill are reflected in the final version of the Clinical Trials Act, patients will be able to claim for bodily injury resulting from participation in clinical trials (non-fault insurance – despite giving their informed consent for a clinical trial, patients may be awarded damages for bodily injury; at present, the liability of sponsors and investigators is fault-based).
The assumptions upon which the bill is based also include a proposal to pay not only healthy subjects but also patients suffering from illness who participate in phase I trials.

“Tidying up” of legislation to stimulate market growth

In the opinion of the respondents to the PMR survey, the “tidying up” of the relevant legislation is a factor which could have the most extensive effect on the development of the market in the next few years. “Respondents cited measures such as a clear-cut definition of a sponsor’s duties, the liberalisation of the law (which is too detailed), and the introduction of transparent and consistent guidelines applicable to all of the parties involved” says Monika Stefanczyk, a PMR Head Pharmaceutical Market Analyst and the report co-author.
There is no single statutory instrument in force in Poland which could regulate the clinical research market comprehensively. The relevant provisions pertaining to the clinical trials market are contained in a number of legal instruments of various categories, including those relating solely to the pharmaceutical market (e.g. the Pharmaceutical Act), but also to the Civil Code and the Penal Code. It is frequently the case that the provisions of legal instruments are inconsistent with each other.
In the opinion of almost 40% of respondents, the key market growth factor is the simplification of the trial registration procedure at the CEBK. However, this view was taken by significantly fewer respondents than in previous surveys carried out by PMR, in 2006 and 2008. In comparison with 2006 and 2008, significantly more respondents identified improvements in public awareness of clinical trials as a key factor which could drive market development. This could be because of the negative media coverage of clinical trials and unfavourable reports on the clinical trials market published in the Polish press in recent years.



This press release is based on information contained in the latest PMR report entitled “Clinical trials in Poland 2010. Development forecasts for 2010-2012”.

For more information on the report please contact:
Marketing Department:
tel. /48/ 12 618 90 00
e-mail: marketing@pmrcorporate.com

About PMR

http://www.pmrpublications.com/_i/images/pclip_image006.jpg

PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research). Being present on the market since 1995, employing highly skilled staff, offering high international standards in projects and publications, providing one of most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.

PMR
ul. Supniewskiego 9, 31-527 Krakow, Poland
tel. /48/ 12 618 90 00, fax /48/ 12 618 90 08
www.pmrcorporate.com

0    submitted by PMR Publications

• Komen reversal a messy reminder
• Don’t lace up to ‘Race for the Cure’ just yet
• Cicero Demolition Awarded to B.L. Duke Inc. Chicago IL
• Carnival Cruise Floats Settlement Offer to Capsized Costa Concordia Cruise Passengers
• This isn't just about Catholics vs. Obama - this is also about women
• Saving for a financial safety net
• Best Honeymoons – Exotic Costa Rica
• Costa Rica Eco-tours – Exploring Life
• Media Critical of Controversial Crisis Communications Counsel Conferred to Carnival Cruise Chairman, Micky Arison
• Costa Rica's Best Adeventures
• News Tip: Mainstream Misses Money Shot
• The Maximus Group names Victor Pap Vice President of Marketing and Outreach
• Driving Yourself in Costa Rica
• Has Capsized Costa Concordia’s Crisis Communications Management Preserved Consumer Confidence for Sailing and Saved Carnival Stock from Sinking? Part II, A Crisis Communications Case Study.
• Costa Rica - Giant Leatherback Turtles of Playa Grande
• Costa Rica Vacations – Why to Visit Tamarindo
• Costa Rica All Inclusive – Luxury in Paradise
• The Laser Warehouse Builds State-of-the-Art Quality Control and Testing Lab
• MEDIA ALERT: March for Life weekend full of events
• Will Crippled Costa Concordia Capsize Carnival Cruise Lines and Crush the Cruise Industry?